Topics

Grifols Wins Early FDA OK For SCIg Xembify, Setting Stage For Margin Growth

08:41 EDT 5 Jul 2019 | SCRIP

Analysts said Grifols is poised for profit margin growth after the US FDA approved its first 20% subcutaneous immunoglobulin, Xembify...

      

Related Stories

 

Original Article: Grifols Wins Early FDA OK For SCIg Xembify, Setting Stage For Margin Growth

NEXT ARTICLE

More From BioPortfolio on "Grifols Wins Early FDA OK For SCIg Xembify, Setting Stage For Margin Growth"

Quick Search

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...